US panel knocks efficacy of Arpida's iclaprim for skin infections

The US FDA's outside advisors soundly recommended against approval of [C#200400415:Arpida]'s iclaprim on November 20th, saying the company failed to establish that the antibacterial's efficacy was non-inferior to linezolid in treating complicated skin and skin structure infections (cSSSI).